Literature DB >> 10550147

Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules.

A Gasbarri1, M P Martegani, F Del Prete, T Lucante, P G Natali, A Bartolazzi.   

Abstract

PURPOSE: Thyroid cancer is the most frequently occurring endocrine malignancy; however, preoperative diagnosis of some lesions, in particular those with follicular histology, is difficult, and a consistent number of not otherwise-specified "follicular nodules" are surgically resected more for diagnosis than therapeutic purposes. In this study, we investigated whether the lectin-related molecules CD44v6 and galectin-3, the expression of which is altered during deregulated cell growth and malignant transformation, could be potential markers for improving the diagnostic accuracy of conventional cytology.
MATERIALS AND METHODS: A comparative immuno-chemical and molecular analysis was performed on 157 thyroid specimens representative of normal, benign, and malignant tissues, and on 36 cytologic samples obtained preoperatively by fine-needle aspiration biopsy from nonselected patients with palpable thyroid nodules.
RESULTS: Normal thyrocytes did not express galectin-3 nor CD44v6. Although the expression of CD44v6 isnegligible in thyroiditis, these molecules are variably detected in benign and malignant proliferative lesions. Interestingly, galectin-3 is never expressed in benign lesions, but it is invariably detected in cancers. A comparative evaluation of CD44v6 and galectin-3 expression in thyroid malignancies demonstrated that these molecules are coexpressed at the messenger RNA and protein level in almost all lesions.
CONCLUSION: Our findings suggest that CD44v6 and galectin-3 could be potential markers to preoperatively identify malignant transformed thyrocytes. Immunodetection of these molecules on cytologic specimens obtained by fine-needle aspiration biopsy is an accurate and improved method for selecting, on a molecular basis, those nodular lesions of the thyroid gland that need to be surgically resected.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10550147     DOI: 10.1200/JCO.1999.17.11.3494

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  28 in total

Review 1.  Distinguishing benign from malignant thyroid lesions: galectin 3 as the latest candidate.

Authors:  R V Lloyd
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

Review 2.  Expression of galectins in cancer: a critical review.

Authors:  Frédéric van den Brûle; Stèphane Califice; Vincent Castronovo
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

Review 3.  Diagnostic role of galectin-3 in follicular thyroid tumors.

Authors:  Marco Volante; Francesca Bozzalla-Cassione; Fabio Orlandi; Mauro Papotti
Journal:  Virchows Arch       Date:  2004-03-04       Impact factor: 4.064

4.  Human galectin-3 immunoexpression in thyroid follicular adenomas with cell atypia.

Authors:  C Nucera; E Mazzon; B Caillou; M A Violi; M Moleti; C Priolo; G Sturniolo; D Puzzolo; V Cavallari; F Trimarchi; F Vermiglio
Journal:  J Endocrinol Invest       Date:  2005-02       Impact factor: 4.256

5.  Utility of immunohistochemical markers in diagnosis of follicular cell derived thyroid lesions.

Authors:  Hanan AlSaeid Alshenawy
Journal:  Pathol Oncol Res       Date:  2014-03-23       Impact factor: 3.201

6.  Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies.

Authors:  Marc-André Fortin; Alexei V Salnikov; Marika Nestor; Nils-Erik Heldin; Kristofer Rubin; Hans Lundqvist
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-02-03       Impact factor: 9.236

7.  Distinguishing molecular markers in thyroid tumors: a tribute to Dr. Orlo Clark.

Authors:  Martha A Zeiger
Journal:  World J Surg       Date:  2009-03       Impact factor: 3.352

8.  Surgical treatment of thyroid follicular neoplasms: results of a retrospective analysis of a large clinical series.

Authors:  Giovanni Conzo; Nicola Avenia; Gian Luca Ansaldo; Piergiorgio Calò; Maurizio De Palma; Chiara Dobrinja; Giovanni Docimo; Claudio Gambardella; Marica Grasso; Celestino Pio Lombardi; Maria Rosa Pelizzo; Angela Pezzolla; Luciano Pezzullo; Micaela Piccoli; Lodovico Rosato; Giuseppe Siciliano; Stefano Spiezia; Ernesto Tartaglia; Francesco Tartaglia; Mario Testini; Giancarlo Troncone; Giuseppe Signoriello
Journal:  Endocrine       Date:  2016-04-13       Impact factor: 3.633

9.  Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid.

Authors:  Marco Volante; Francesca Bozzalla-Cassione; Roberta DePompa; Enrico Saggiorato; Armando Bartolazzi; Fabio Orlandi; Mauro Papotti
Journal:  Virchows Arch       Date:  2004-07-14       Impact factor: 4.064

10.  Sensitivity and Specificity of Galectin-3 and Glypican-3 in Follicular-Patterned and Other Thyroid Neoplasms.

Authors:  Dalia Rifaat Al-Sharaky; Sheren Fouad Younes
Journal:  J Clin Diagn Res       Date:  2016-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.